Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study
Copyright © 2020. Published by Elsevier Inc..
BACKGROUND: Lower extremity peripheral arterial disease (PAD) is a public health problem and many patients with PAD experience claudication despite adequate medical and/or surgical management. Mobilization of endogenous progenitor cells using Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a novel therapeutic option that has shown promising results in experimental models and phase I/IIA clinical trials. The GPAD-3 trial will study the effect of two successive administrations of GM-CSF at 3-month interval for improving claudication among patients with lower extremity PAD.
METHODS: We plan to recruit 176 patients in this ongoing randomized, double-blind, placebo-controlled Phase IIB trial. After screening for inclusion and exclusion criteria, eligible subjects undergo a 4-week screening phase where they perform subcutaneous placebo injections thrice weekly and walk at least three times a day until they develop claudication. After the screening phase, eligible subjects undergo baseline testing and are randomized 2:1 to receive 500 μg/day of GM-CSF subcutaneously thrice weekly for three weeks or placebo injections. After 3 months, follow-up endpoint testing is performed and subjects in the GM-CSF group receive the second administration of the drug for three weeks while subjects in placebo group receive matching placebo injections. All participants undergo endpoint testing at six-month and nine-month follow-up. The primary endpoint is change in 6-min walk distance between baseline and 6-month follow-up.
CONCLUSION: GPAD-3 explores a novel approach to address the need for alternative therapies that can alleviate symptoms among patients with lower extremity PAD. If successful, this study will pave the way for a pivotal Phase III trial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 91(2020) vom: 02. Apr., Seite 105975 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mehta, Anurag [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.08.2021 Date Revised 20.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT03304821 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cct.2020.105975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307338401 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307338401 | ||
| 003 | DE-627 | ||
| 005 | 20240320232505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2020.105975 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM307338401 | ||
| 035 | |a (NLM)32145440 | ||
| 035 | |a (PII)S1551-7144(20)30053-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mehta, Anurag |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2021 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03304821 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Lower extremity peripheral arterial disease (PAD) is a public health problem and many patients with PAD experience claudication despite adequate medical and/or surgical management. Mobilization of endogenous progenitor cells using Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a novel therapeutic option that has shown promising results in experimental models and phase I/IIA clinical trials. The GPAD-3 trial will study the effect of two successive administrations of GM-CSF at 3-month interval for improving claudication among patients with lower extremity PAD | ||
| 520 | |a METHODS: We plan to recruit 176 patients in this ongoing randomized, double-blind, placebo-controlled Phase IIB trial. After screening for inclusion and exclusion criteria, eligible subjects undergo a 4-week screening phase where they perform subcutaneous placebo injections thrice weekly and walk at least three times a day until they develop claudication. After the screening phase, eligible subjects undergo baseline testing and are randomized 2:1 to receive 500 μg/day of GM-CSF subcutaneously thrice weekly for three weeks or placebo injections. After 3 months, follow-up endpoint testing is performed and subjects in the GM-CSF group receive the second administration of the drug for three weeks while subjects in placebo group receive matching placebo injections. All participants undergo endpoint testing at six-month and nine-month follow-up. The primary endpoint is change in 6-min walk distance between baseline and 6-month follow-up | ||
| 520 | |a CONCLUSION: GPAD-3 explores a novel approach to address the need for alternative therapies that can alleviate symptoms among patients with lower extremity PAD. If successful, this study will pave the way for a pivotal Phase III trial | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Angiogenesis | |
| 650 | 4 | |a Claudication | |
| 650 | 4 | |a GM-CSF | |
| 650 | 4 | |a Peripheral artery disease | |
| 650 | 7 | |a Granulocyte-Macrophage Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 83869-56-1 |2 NLM | |
| 700 | 1 | |a Mavromatis, Kreton |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Yi-An |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Steven C |e verfasserin |4 aut | |
| 700 | 1 | |a Dhindsa, Devinder S |e verfasserin |4 aut | |
| 700 | 1 | |a Goodwin, Cydney |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Risha |e verfasserin |4 aut | |
| 700 | 1 | |a Martini, Mohammad A |e verfasserin |4 aut | |
| 700 | 1 | |a Prasad, Mahadev |e verfasserin |4 aut | |
| 700 | 1 | |a Mokhtari, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Hesaroieh, Iraj G |e verfasserin |4 aut | |
| 700 | 1 | |a Frohwein, Stephen C |e verfasserin |4 aut | |
| 700 | 1 | |a Kutner, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Harzand, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Bryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Duwayri, Yazan |e verfasserin |4 aut | |
| 700 | 1 | |a Alabi, Olamide |e verfasserin |4 aut | |
| 700 | 1 | |a Rajani, Ravi R |e verfasserin |4 aut | |
| 700 | 1 | |a Brewster, Luke P |e verfasserin |4 aut | |
| 700 | 1 | |a Waller, Edmund K |e verfasserin |4 aut | |
| 700 | 1 | |a Quyyumi, Arshed A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d 2005 |g 91(2020) vom: 02. Apr., Seite 105975 |w (DE-627)NLM154869031 |x 1559-2030 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2020 |g day:02 |g month:04 |g pages:105975 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cct.2020.105975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2020 |b 02 |c 04 |h 105975 | ||